MannKind Corporation (MNKD)
Nasdaq · Healthcare · Biotechnology
$3.82+0.53%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $1.2B
- Forward P/E
- 30.0
- 52-week range
- $2.23 – $6.51
- 52-week change
- −32.74%
- EPS (trailing)
- −$0.14
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $349M (+22.23%)
- Net income
- $5.9M
- Operating margin
- 11.1%
- Diluted EPS
- $0.02
- Free cash flow
- $13.7M
From the company’s annual report on SEC EDGAR.
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide.
Headquarters: Danbury, United States · 591 employees · mannkindcorp.com